Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Immuneering Corporation (IMRX)

4.45   0.04 (0.91%) 01-27 16:00
Open: 4.39 Pre. Close: 4.41
High: 4.7 Low: 4.35
Volume: 33,484 Market Cap: 118(M)

Technical analysis

as of: 2023-01-27 4:45:29 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 5.84     One year: 6.82
Support: Support1: 4.3    Support2: 3.86
Resistance: Resistance1: 5    Resistance2: 5.84
Pivot: 4.34
Moving Average: MA(5): 4.38     MA(20): 4.34
MA(100): 8.46     MA(250): 7.21
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 61.9     %D(3): 54.8
RSI: RSI(14): 46.3
52-week: High: 16.16  Low: 3.74
Average Vol(K): 3-Month: 41 (K)  10-Days: 36 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IMRX ] has closed below upper band by 38.3%. Bollinger Bands are 78.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.7 - 4.73 4.73 - 4.75
Low: 4.3 - 4.32 4.32 - 4.34
Close: 4.41 - 4.45 4.45 - 4.48

Company Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Headline News

Thu, 19 Jan 2023
News & Products for the week of January 16th 2023 - TRAINS Magazine

Wed, 18 Jan 2023
7 Cheap But Risky Biotech Stocks - Barron's

Sun, 18 Dec 2022
Immuneering Corporation's (NASDAQ:IMRX) top holders are insiders and they are likely disappointed by the recent 19% drop - Simply Wall St

Thu, 10 Nov 2022
Immuneering Reports Third Quarter 2022 Financial Results and ... - GlobeNewswire

Thu, 20 Oct 2022
Immuneering Appoints Leah R. Neufeld as Chief People Officer - GlobeNewswire

Wed, 05 Oct 2022
Immuneering To Present Poster on IMM-6-415 at the 37th Annual ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 26 (M)
% Held by Insiders 1.385e+007 (%)
% Held by Institutions 30.5 (%)
Shares Short 777 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.867e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -9
Return on Assets (ttm) 657.5
Return on Equity (ttm) -20.6
Qtrly Rev. Growth 506090
Gross Profit (p.s.) 0.03
Sales Per Share 0.09
EBITDA (p.s.) -1.09
Qtrly Earnings Growth -2.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 45.75
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 882620
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.